Does VEDOLIZUMAB Cause Hepatic neoplasm? 12 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 12 reports of Hepatic neoplasm have been filed in association with VEDOLIZUMAB (ENTYVIO). This represents 0.0% of all adverse event reports for VEDOLIZUMAB.
12
Reports of Hepatic neoplasm with VEDOLIZUMAB
0.0%
of all VEDOLIZUMAB reports
0
Deaths
5
Hospitalizations
How Dangerous Is Hepatic neoplasm From VEDOLIZUMAB?
Of the 12 reports, 5 (41.7%) required hospitalization, and 1 (8.3%) were considered life-threatening.
Is Hepatic neoplasm Listed in the Official Label?
Yes, Hepatic neoplasm is listed as a known adverse reaction in the official FDA drug label for VEDOLIZUMAB.
What Other Side Effects Does VEDOLIZUMAB Cause?
Off label use (21,017)
Colitis ulcerative (13,455)
Crohn's disease (9,759)
Drug ineffective (8,424)
Diarrhoea (7,493)
Abdominal pain (6,401)
Fatigue (5,477)
Haematochezia (5,215)
Frequent bowel movements (4,527)
Arthralgia (4,028)
What Other Drugs Cause Hepatic neoplasm?
OCTREOTIDE (300)
ADALIMUMAB (98)
LANREOTIDE (85)
EVEROLIMUS (84)
AMLODIPINE (74)
ROSUVASTATIN (55)
IMATINIB (51)
BEVACIZUMAB (49)
RIBAVIRIN (49)
METFORMIN (47)
Which VEDOLIZUMAB Alternatives Have Lower Hepatic neoplasm Risk?
VEDOLIZUMAB vs VELAGLUCERASE ALFA
VEDOLIZUMAB vs VELCADE
VEDOLIZUMAB vs VELETRI
VEDOLIZUMAB vs VELIPARIB
VEDOLIZUMAB vs VEMURAFENIB